Membership Type:
Member
Center:
CILG
Awarded in: 2025
Email: emanuele.andreano [@] biotecnopolo.it
Profile
Dr. Emanuele Andreano is Head of Serology and Immunology at Fondazione Biotecnopolo di Siena and the National Center for Pandemic Preparedness (CNAP), Siena, Italy. His work focuses on the human B cell response to infectious agents and on the isolation of human monoclonal antibodies (mAbs) to fight pandemics and global health threats.
Among his most significant achievements, Dr. Andreano anticipated the emergence of SARS-CoV-2 variants months before they appeared in the real world and predicted that this virus could evade natural and vaccine immunity. He also discovered and led the development of MAD0004J08, one of the few mAbs developed in Europe for the treatment of COVID-19 which reached phase II/III clinical development. Dr. Andreano has also decoded the global phenomenon of "original antigenic sin" in COVID-19 immunity and discovered that hybrid immunity is superior to infection or vaccination alone. In his most recent work, Dr. Andreano identified bactericidal mAbs against Neisseria gonorrhoeae, a WHO-designated priority pathogen due to rising antibiotic resistance.
He served as first or corresponding author of numerous publications in top tire journals (Nature, Nature Medicine, Cell, Science Translational Medicine, Science Immunology, PNAS). In 2023 he was named a “Rising Star in Immunology” by the International Union of Immunological Societies, and in 2025 received the “Antonio Feltrinelli Giovani” awards, Accademia dei Lincei, at the presence of the President of the Italian Republic.